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AbstrAct
Introduction Intervention studies have mainly used 
oral nutritional supplements (ONS) for the management 
of patients with chronic obstructive pulmonary disease 
(COPD) identified as at nutritional risk. In this 12-month 
randomised feasibility trial, we assessed the (1) feasibility 
of the recruitment, retention and provision of two 
interventions: ONS and between-meal snacks (snacks) and 
(2) the potential impact of the provision of snacks and ONS 
on body weight and quality of life in patients with COPD.
Methods  Hospitalised patients with COPD, at nutritional 
risk, were randomised to ONS (n=19) or snacks (n=15) 
providing 600 kcal and 22 g protein a day in addition to 
regular daily diet. The intervention started in hospital and 
was continued for 12 months after discharge from the 
hospital.
results  Study recruitment rate was n=34 (45%) and 
retention rate at 12 months was similar for both groups: 
n=13 (68%) in the ONS group and n=10 (67%) in the 
Snacks group. Both groups gained weight from baseline 
to 12 months (2.3±4.6 kg (p=0.060) in the ONS group 
and 4.4±6.4 kg (p=0.030) in the Snacks group). The St 
George’s Respiratory Questionnaire total score improved 
from baseline to 12 months in both groups (score 
3.9±11.0 (p=0.176) in the ONS group and score 8.9±14.1 
(p=0.041) in the Snacks group).
Discussion  In patients with COPD who are at nutritional 
risk snacks are at least as feasible and effective as ONS, 
however, adequately powered trials that take account of 
the difficulties in recruiting this patient group are required 
to confirm this effect.
IntroDuctIon
Malnutrition is common in patients with 
chronic obstructive pulmonary disease 
(COPD)1 2 with reported prevalence rates 
between 20% and 45% depending on the 
characteristics of the COPD population, and 
screening tools and cut-off criteria used.1–3 
Malnutrition in patients with COPD is 
associated with an increased risk of compli-
cations, longer hospital stays and increased 
mortality,4–7 leading to an increased economic 
and operational burden for health services.8
Many randomised trials, summarised in 
systematic reviews, have investigated nutri-
tional interventions to treat malnutrition in 
patients with stable COPD.9–11 Most of the 
included studies have demonstrated a positive 
impact on survival, complication rate, length 
of stay (LOS) and hospital readmissions as 
well as some nutritional and patient-centred 
outcomes.9–11 However, the evidence for 
benefit comes mainly from studies using oral 
nutritional supplements (ONS) and often 
comparing ONS to a control group receiving 
no nutritional intervention.9–11
Since the arrival of ‘ready-to-use’ ONS, the 
use of food-based strategies seems to have 
Key messages
 ► Are between-meal snacks and oral nutritional sup-
plements (ONS) feasible and effective on weight 
change and quality of life (QoL) in hospitalised pa-
tients at nutritional risk?
 ► Both groups gained weight of more than 2 kg from 
baseline to 12 months and QoL significantly im-
proved from baseline to 3 months in both groups, 
and improvements from baseline to 12 months were 
of clinically relevant difference in both groups.
 ► Our findings imply that snacks are at least as fea-
sible and effective as ONS and were associated 
in greater improvements in QoL, however, future 
trials should be informed by the recruitment and 
retention issues that have been raised and prac-
tical issues of undertaken functional measures 
in this population merits further consideration. 
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declined12 and data on patient-relevant outcomes are 
lacking.12 13 There are also significant financial and prac-
tical differences associated with ONS and snacks, which, 
in the absence of clear evidence to inform decisions, have 
influenced choice of supplementation method.
In order to investigate the potential role of energy and 
protein-dense food for patients with COPD, the aims of 
this 12-month randomised intervention trial were to study 
the (1) feasibility of the recruitment, retention and provi-
sion of each intervention, and (2) the potential impact of 
the provision of snacks and ONS on body weight, and (3) 
quality of life (QoL) in patients with COPD.
MethoDs
study design and participants
This study was a randomised trial and registered at  Clin-
icalTrials. gov on 25 September 2014 ( ClinicalTrials. gov 
identifier: NCT02251496). The study was conducted in 
line with the Declaration of Helsinki. The study follows 
the Consolidated Standards of Reporting Trials 2010 
statement: extension to randomised pilot and feasi-
bility trials.14
Patients with a clinical diagnosis of COPD who had 
been recently admitted to the Department of Respi-
ratory Medicine at Landspitali University Hospital 
were screened for possible nutritional risk (score ≥4) 
by a trained researcher using a validated nutritional 
screening tool.3 15 The Icelandic Simple Screening 
(ISS) used is recommended by the clinical guide-
lines for hospital nutrition at Landspitali,16 and has 
been validated against a full nutritional assessment in 
patients with COPD3 and predicts mortality in patients 
with COPD.15 ISS gathers information on body mass 
index (BMI), unintentional weight loss, age, comorbid-
ities, recent hospitalisation and a range of symptoms 
that impact nutritional intake during the last weeks 
or months (vomiting, diarrhoea, loss of appetite or 
nausea, difficulties in chewing or swallowing).
All eligible patients who were able to eat orally, and 
had an anticipated length of hospitalisation of >3 
days were invited to participate in the study. The most 
common reason for admission was acute exacerbation 
of COPD. Written informed consent was obtained from 
all participants.
Patients diagnosed with cancer, dysphagia, food 
allergy or intolerance and anatomical obstructions 
preventing oral food intake were excluded. Patients not 
able to sign informed consent due to cognitive issues 
were also excluded.
Sociodemographic data (age, gender and smoking 
status) were collected from electronic medical records 
SAGA (TM software V.3.1.39.9).
randomisation and masking
Eligible patients were randomly assigned in a 1:1 
ratio to either an ONS group (ONS) or Snacks group. 
Random sequence generation was performed using 
randomisation codes produced by Microsoft Excel for 
Windows 2007. Randomisation, allocation of patients 
to groups, nutritional intervention and outcome assess-
ments were performed by one researcher (ARI). Due 
to the nature of the intervention it was not possible to 
perform a blinded study. Randomisation took place 
after screening for nutritional risk and prior to base-
line assessment.
Procedures
This study was originally designed as a randomised trial 
to investigate the effects of snacks on body weight and 
QoL in patients with COPD compared with ONS with 
a planned enrolment of 200 subjects ( ClinicalTrials. 
gov, number NCT02251496). Despite screening 492 
subjects, only 76 were eligible indicating that recruit-
ment is challenging in this population and clinical 
setting. Recruitment rates were lower than expected 
which led to a change in the study protocol to a 
randomised feasibility trial as funding was limited to 
3 years. One reason for low recruitment rates might 
be overstrict inclusion criteria. More details on study 
recruitment are provided in the Results section.
Nutritional screening was undertaken on admission 
using the validated screening tool as recommended for 
use at the Landspitali.3 15 16 A total score of ≥4 is consid-
ered ‘at nutritional risk’.
After providing informed consent, subjects were 
randomly allocated to one of two groups. Subjects in 
group 1 were provided with ONS and subjects in group 
2 were provided with snacks (table 1). The intervention 
started in hospital and was continued for 12 months 
after discharge from the hospital.
Subjects in group 1 were offered a variety of flavours 
and pack sizes of ONS free of charge. As the hospital 
had a contract with Nutricia (Icepharma, Iceland) that 
was the brand used. Subjects in group 2 were provided 
with snacks free of charge, based on common Icelandic 
food products, for example, Icelandic skyr which is a 
high-protein milk product similar to yogurt. Patients in 
both groups were encouraged to consume two or more 
ONS or snacks daily providing approximately 600 kcal/
day and approximately 22 g protein/day in addition 
to regular food depending on which group they were 
in.10 11
The selected ONS were delivered to the patient’s 
home or picked up at the wholesaler and the food pack-
ages were delivered to patient’s home or collected from 
the hospital, according to patient’s preference. It was 
assumed that each delivery of ONS and snacks would 
last for 1 month and 2–3 weeks, respectively. A leaflet 
designed for this study was provided with pictures 
of different ONS or each snack and written advice 
regarding their use such as suggestions on timing of 
intake, choosing a lower volume (125 mL each) when 
appetite was poor (ONS) and choice of different meals 
(snacks). For some items, patients had to portion the 
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Table 1 Nutritional content of each intervention product
Product Portion size Energy (kcal) Protein (g)
Oral nutritional supplement drinks
  Nutridrink compact (Nutricia)
  For example, vanilla, banana, strawberry and chocolate
125 mL 300 12
  Nutridrink compact fibre (Nutricia)
  – vanilla, strawberry and mokka
125 mL 300 12
  Nutridrink (Nutricia)
  – vanilla, strawberry, banana and chocolate
200 mL 300 12
  Nutridrink juice style (Nutricia)
  For example, blackcurrant, apple and orange
200 mL 300 8
  Nutridrink Creme (Nutricia)
  – forest fruit and chocolate
125 g 200 12
Mean 280 11
In-between-meal snack 
  Blueberry skyr with cream (MS Dairies) Skyr 140 g
Cream 20 mL
254 17
  Two mini skyr with cream (MS Dairies)




  Rye bread (Myllan) with liver paté (Ora) and butter (MS 
Dairies)
Rye bread 55 g
Liver paté 40 g
Butter 10 g
313 7
  Pan bread (Myllan) with ham and egg salad (Sómi) Pan bread 47 g
Salad 55 g
262 8
  Oat biscuits (Frón) with butter, cheese and glass of milk 
(MS Dairies)





  Nutbar (Himneskt) with milk (MS Dairies) Nutbar 40 g
Milk 150 mL
302 10
  Cheesecake (MS Dairies)
  – raspberry and chocolate
100 g 322 6
Mean 286 11
snacks themselves, for example, a whole cheesecake, 
because the minimal available pack size was more than 
one portion.
Verbal advice on the use of each intervention was also 
given to both groups, for example, ONS should be used 
from the fridge and snacks with less expiry date should 
be used first.
All patients could phone the study investigator if 
they needed more ONS or snacks, and every month 
each patient received a call to ascertain the quantity 
remaining. If patients were admitted to hospital during 
the study period they received ONS or snacks according 
to randomisation during their hospital stay.
During every follow-up appointment and during any 
hospital readmissions similar time was spent with each 
group.
outcomes
Outcomes related to feasibility were percentage of 
eligible subjects that accepted participation (recruit-
ment), percentage of included subjects that finished 
the 12-month intervention period (retention), the 
feasibility of undertaking functional assessment and 
use of ONS/snacks assessed by 24-hour recalls (compli-
ance).
The primary outcome was efficacy of the interventions 
assessed as weight change from baseline to 1 year from 
admission to the hospital. Assessment of body compo-
sition, that is, fat mass (FM), fat-free mass (FFM) and 
muscle mass, was conducted using a portable, multi-
frequency (20 kHz, 100 kHz) bioelectrical impedance 
analysis device (InBody230, Korea). The method has 
previously been validated in patients with stable COPD.5
The secondary outcome measures were QoL measured 
using the St George’s Respiratory Questionnaire (SGRQ). 
This validated questionnaire is based on 76 items used 
to calculate three component scores: symptoms, activity 
and impact, and a total score. A score of 100 represents 
worst possible health status and a score of 0 represents 
best possible health status.17 A change of 4 points in the 
SGRQ total score is considered the minimum clinically 
relevant difference.18
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Other outcome measures included were forced expi-
ratory volume in 1 s (FEV1) and forced vital capacity 
(FVC) measured by spirometry (Jaeger MS-PFT, Care 
Fusion, San Diego, USA).19 Functional performance 
using several tests validated in patients with COPD were 
included: 6 min walk distance (6MWD),20 timed up and 
go (TUG),21 30 s chair stand22 and hand grip strength 
(HGS)23 measured by a handheld dynamometer (Jamar 
Sammons Preston Rolyan, Bolingbrook, IL, USA), and 
energy and protein intake during hospital stay and at 
home (2 and 4 weeks after discharge).
Total energy and protein intake during hospital stay 
was estimated using a validated plate diagram sheet24 25 
for 3 days, starting on the first day of participation in 
the study and after the intervention had started.
Energy and protein intake at home was assessed 
using the 24-hour recall method,26 2 and 4 weeks after 
hospital discharge, and analysed using the ICEFOOD 
nutritional analysis programme.27 For full details of 
study assessments, see online supplementary appendix 
1.
statistical analysis
All statistical analyses were undertaken using IBM SPSS 
Statistics V.24 and the level of significance was set at 
0.05.
Our original power calculations were based on the 
primary outcome of difference in weight gain between 
the groups and change in weight to 1 year. Due to low 
recruitment rate and lower participation rates than 
expected, post hoc power calculations were performed 
based on our results.
The Kolmogorov-Smirnov test was used to test data 
normality. The independent t-test was used to test for 
differences between continuous data at baseline and the 
Pearson’s χ2 test was used for categorical data. Intention-
to-treat analyses were conducted where the last observa-
tions were carried forward and used to assess treatment 
efficacy. All patients with at least two measures (base-
line and one other) were included. Repeated measures 
analysis of covariance was conducted to analyse mean 
changes in each follow-up.
results
Feasibility
A total of 492 COPD subjects were screened for nutri-
tional risk in the Department of Pulmonary Medicine 
at Landspitali from September 2014 to December 2016. 
A total of 145 (30%) were identified at nutritional risk 
(score ≥4).
recruitment and retention in the study
Thirty-four (45%) of the 76 eligible patients consented 
to take part in the study, 19 were randomised to the 
ONS group and 15 to the Snacks group. A total of 42 
(55%) refused to participate (figure 1). Those who 
refused to participate were significantly heavier than 
those who participated (61.9 kg vs 51.4 kg, p<0.001) 
and had higher BMI (21.8 kg/m2 vs 18.6 kg/m2, 
p<0.001). Of those 42 subjects who refused to partic-
ipate, 6 (14%) were afraid of gaining weight, 3 (7%) 
did not like using ONS or snacks, 14 (33%) found the 
demands of the study quite heavy considering their 
clinical condition, 5 (12%) had practical issues with 
coming to clinic, 4 (10%) were already participating 
in another study outside the pulmonary unit and were 
unwilling to participate in two studies and 10 (24%) 
gave no reason for their refusal.
Twenty-three (68%) of 34 participants completed the 
12-month study period. The proportion was similar in 
each group (figure 1). Of the 11 patients who did not 
complete the study, two withdrew due to illness and 
seven died. One repeatedly cancelled appointments 
and one was unable to be contacted. Three patients 
were readmitted within the first 30 days of the study 
(n=2 in the ONS group and n=1 in the Snacks group). 
There was no difference in cumulative LOS over 12 
months between groups (median 40 days (95% CI 14 
to 82) in the ONS group and median 46 days (95% 
CI 9 to 73) in the Snacks group). The total number of 
admissions to the hospital over the 12 months was 24 
in the ONS group and 22 in the Snacks group. Compli-
ance with both interventions in the early postdischarge 
period was either adequate (2–3 ONS/snacks per day) 
or greater than recommended (≥4 ONS/snacks per 
day).
Feasibility of undertaking functional assessments
The lowest retention rate was in the 6MWD with 12 
(35%) patients completing the assessment at 12 months 
of follow-up, n=15 (44%) completed the TUG, n=15 
(44%) 30 s chair stand and n=19 (56%) HGS. The most 
common reasons for not completing the functional 
tests were weakness, dyspnoea and fatigue.
efficacy
Table 2 shows the baseline characteristics of the subjects.
Change in weight and body composition
Both groups tended to increase in body weight from 
baseline to 12 months (table 3). Mean per cent weight 
change from baseline to 12 months is shown in figure 2. 
We are not able to compare the difference between 
groups as a sample size of 176 subjects (88 subjects in 
each group) would have been needed to detect a differ-
ence of 2 kg in weight gain between the groups over 12 
months period (statistical power of 0.8 and a p value of 
0.05).
A significant increase in FM was seen in both groups. 
While there was a tendency towards decreased FFM 
from baseline to 12 months in the ONS groups, partic-
ipants in the Snacks groups seemed to preserve their 
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Figure 1 Consolidated Standards of Reporting Trials (CONSORT) diagram. Study flow chart. ONS, oral nutritional 
supplements.
FFM. However, changes in FFM from baseline to 12 
months were not statistically significant (table 3).
Weight loss from baseline to 12 months was observed 
in 7 (24%) patients (n=5 in ONS and n=2 in the Snacks 
group). Participants who lost weight were signifi-
cantly older than those who gained weight (77 (8.7) 
years vs 69 (6.7) years, p=0.006). There was a tendency 
towards higher BMI at baseline in those who lost weight 
compared with those who were weight stable or gained 
weight (20.5 (3.2) kg/m2 vs 17.8 (3.0) kg/m2, p=0.054), 
but no significant difference was seen in other variables, 
for example, smoking status, occupation and QoL.
Change in QoL
SGRQ total score significantly improved from baseline 
to 3 months in both groups (table 4). This improvement 
was maintained at 12 months in the Snacks group 
(score improved by 8.9 (14.1) points, p=0.041); 
however, QoL declined in the ONS group as the study 
progressed resulting in no significant difference at 12 
months (improvements by 3.9 (11.0) points, p=0.176). 
Improvement in SGRQ total score was mainly attribut-
able to improvements in symptom scores.
energy and protein intake
Total energy intake was significantly higher after hospital 
discharge than at baseline (in hospital) in both groups 
(figure 3). In the Snacks group, protein intake was signif-
icantly higher at 2–4 weeks after discharge than during 
hospitalisation (1.8 g/kg/day vs 1.4 g/kg/day, respec-
tively, p=0.048), while the increase in protein intake in 
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Table 2 Subjects’ characteristics at baseline
ONS Snacks
P value* n=19 n=15
Sex 
  Male† 32 27 0.755
  Female† 68 73
Age (years)‡ 72 (8) 73 (8) 0.852
Height (cm)‡ 167 (11) 164 (10) 0.473
Weight (kg)‡ 54 (10) 49 (10) 0.170
Body mass index (kg/m2)‡ 19.4 (4.1) 18.0 (2.7) 0.271
Body fat mass (kg)§ 8.0 (3.3 to 
16.2)
8.7 (3.2 to 
10.1)
0.781
Fat-free mass (kg)‡ 43.6 (10.5) 39.9 (8.5) 0.277
Fat-free mass index (kg/m2)‡ 13.0 (2.8) 12.1 (1.9) 0.280
Lung function 
  FEV1 (% of predicted)‡ 37.2 (16.3) 37.3 (9.5) 0.971
  FVC (% of predicted)‡ 64.7 (15.9) 66.9 (21.3) 0.726
Smoking status 
  Smokers† 26 40 0.397
  Ex-smokers† 63 60
  Non-smokers† 11 0
Quality of life (SGRQ) 
  Symptom score‡ 65.1 (18.1) 62.6 (20.8) 0.716
  Activity score‡ 76.5 (29.1) 73.0 (17.1) 0.690
  Impact score‡ 54.6 (22.9) 46.4 (19.1) 0.290
  Total score‡ 63.2 (21.1) 57.2 (16.5) 0.391
Nutritional risk 
  Score 4–5† 26 27 0.990
  Score 6–7† 26 27
  Score 8–9† 42 40
  Score ≥10† 6 6
6MWD (m)‡ 234 (108) 185 (90) 0.194
HGS (kg)‡ 15 (8) 14 (7) 0.785
TUG (s)§ 15.6 (9.7 to 
19.8)
15.0 (11.4 to 
17.8)
0.841
30 s chair stand (n)‡ 3.7 (4.0) 5.6 (3.0) 0.160
In-hospital physiotherapy† 58 67 0.424
*P value for independent t-test for continuous data (age, height, weight, body 
mass index, fat-free mass, fat-free mass index, FEV1, FVC, SGRQ scores, 
6MWD, HGS and 30 s chair stand), Mann-Whitney test for non-parametric 
data (body fat mass and TUG) and Pearson’s χ2 test for categorical data 
(gender, smoking status, nutritional risk score and in-hospital physiotherapy).
†Data shown as %.
‡Data shown as mean (SD).
§Data shown as median (95% CI).
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; HGS, 
hand grip strength; 6MWD, six min walking distance; ONS, oral nutritional 
supplements; SGRQ, St George’s Respiratory Questionnaire; TUG, timed up 
and go.
the ONS group was not statistically significant (1.4 g/kg/
day vs 1.2 g/kg/day, p=0.213).
Change in lung function, functional measures and muscle strength
No significant changes in lung function (FEV1 and 
FVC) were seen between baseline and 12 months in 
either group. Similarly, functional measures and muscle 
strength remained stable from baseline to 12 months in 
both groups (see online supplementary table 1).
DIscussIon
Feasibility
Recruitment and retention in the study
In our study, more than half the eligible participants 
(55%) refused to take part and one-third of them found 
the demands of the study burdensome considering 
their clinical condition. Although similar participation 
rates have been seen in other nutritional intervention 
studies in patients with COPD,28 29 it can be speculated 
that in a study of such long duration and with as many 
follow-up visits, including tests related to physical func-
tion, recruiting patients from outpatient clinics might be 
more feasible than recruiting patients with exacerbations 
of disease in the hospital setting.
The retention rate after the 12-month intervention 
period was 68% and was similar for both groups. The 
most common reasons for not attending follow-up visits 
were weakness and length of the visits. Seven patients 
passed away and two withdrew due to the heavy burden 
of study assessments. A similar retention rate was seen 
in a study by Weekes et al with 56% of the participants 
completing the study.28
Feasibility of undertaking functional assessments
The number of outcomes measured in the present study 
was extensive. Giving the challenges in getting people 
to attend follow-up visits and therefore the number of 
participants on whom data were gathered, the number 
of outcome measures should be minimised and assess-
ments planned to be undertaken in the patient’s home 
to prevent excessive participant burden in future studies. 
Furthermore, there were difficulties in measuring some 
of the secondary outcomes in those who attended 
follow-up visits. The reasons might be that majority of our 
study group (88%) had severe or very severe disease at 
baseline and as the study continued deterioration in clin-
ical condition was seen in part of the study population.
efficacy
Change in weight and body composition
A weight gain of more than 2 kg has been shown to be a 
significant predictor of survival in depleted and non-de-
pleted patients with COPD.30 In our study, both groups 
gained weight from baseline to 12 months. While the 
Snacks group tended to gain more weight than the ONS 
group (4.4 (6.4) kg (p=0.030) and 2.3 (4.6) kg (p=0.060), 
respectively), we do not have statistical power to detect 
significant difference between groups.
Significant weight gain in favour of supplementation 
and significant change from baseline in FFM and FM were 
seen among patients with COPD in a systematic review by 
Ferreira et al.11 However, only three of the included studies 
assessed changes in FFM in undernourished patients and 
in all those studies nutritional support was combined with 
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Table 3 Mean change (SD) (kg) in body composition from baseline to each follow-up
ONS Snacks
3 months 6 months 9 months 12 months 3 months 6 months 9 months 12 months
Weight (kg) 2.1 (4.3) 2.2 (4.7) 2.1 (4.5) 2.3 (4.6) 2.7 (4.4)* 3.6 (5.3)* 3.4 (6.4) 4.4 (6.4)*
Fat mass (kg) 4.4 (6.4)* 3.9 (5.4)* 4.0 (5.0)* 3.7 (4.9)* 3.2 (4.5)* 2.8 (3.7)* 3.1 (4.8)* 2.9 (4.8)
Fat-free mass (kg) −2.3 (5.4) −1.7 (5.5) −1.9 (6.0) −1.3 (5.8) −0.1 (3.3) 2.0 (6.0) 0.8 (6.3) 1.8 (6.1)
Fat-free mass index 
(kg/m2)
−0.7 (1.6) −0.5 (1.7) −0.6 (1.8) −0.4 (1.7) 0.0 (0.9) 0.5 (1.6) 0.1 (1.8) 0.5 (1.7)
Total body water (kg) −1.5 (3.8) −1.1 (3.8) −1.3 (4.2) −0.8 (4.1) −0.1 (1.6) 1.3 (3.9) 0.4 (4.1) 1.1 (4.0)
Data shown as mean (SD). Intention-to-treat analysis. Groups: ONS (n=16), Snacks (n=13).
ONS, oral nutritional supplements.
*Significantly different from baseline, p<0.05.
Figure 2 Mean weight change (%) from baseline. Intention-to-treat analysis. Groups: ONS, oral nutritional supplements 
(n=16), Snacks (n=13).
an exercise rehabilitation programme.31–33 In the study by 
Weekes et al, the intervention group maintained muscle 
mass and increased FM while in the control group both 
muscle mass and FM declined. None of their patients 
were undertaking pulmonary rehabilitation at the time.28 
In our study, there was an increase in FM in both groups. 
However, only participants in the Snacks group tended 
to increase FFM over time while there was a tendency 
towards a decrease in the ONS group. One reason might 
be higher protein intake/kg/day in the Snacks group, 
with an estimated protein intake of 1.8 g/kg/day 2–4 
weeks after discharge from the hospital compared with 
1.4 g/kg/day in the ONS group. Unfortunately, we do 
not have estimates of protein intake later in the study 
period. In contrast to our study, a study by Collins et al 
found protein intake after 3 months was higher in the 
group receiving ONS compared with the group receiving 
dietary advice although they did not assess FFM.29
Quality of life
In the present study, QoL improved significantly from 
baseline to 3 months in both groups, however, only the 
Snacks group maintained the improvement at 12 months 
(improvements of 3.9 points in the ONS group and 8.9 
points in the Snacks group). This is important since a 
change of 4 points in SGRQ total score is considered a 
minimum clinically relevant difference.18 Other studies 
have shown that nutritional intervention does appear 
to have an impact; however, the size of the effect varies 
between studies, perhaps due to the timing of the inter-
vention, for example, in hospital or several months later, 
whether or not they were receiving pulmonary rehabilita-
tion, and so on.28 32
It is a strength that this is one of the longest nutrition 
intervention studies reported in patients with COPD, 
where other studies mostly using ONS tended to last for 
3–6 months.9–11 However, information on what happened 
after intervention in our study is lacking. The Snacks 
group might continue to consume food similar to what 
was provided in the study as they are ordinary foods 
which can be bought in a grocery store. However, the 
ONS group might not unless ONS are subsidised from 
the health insurance.
To our knowledge, only one study in muscle-wasted 
patients with COPD had longer follow-up than ours 
(24 months), with nutritional intervention only for 4 
months.32 Significant increase in BMI (1.1 (SE 0.37) kg/
m2) was seen from baseline to 24 months of follow-up 
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Table 4 Quality of life (SGRQ)
ONS Snacks
Baseline 3 months 12 months Baseline 3 months 12 months
Activity score 75.0 (30.5) 71.4 (30.2) 78.3 (21.3) 71.5 (16.8) 68.8 (18.8) 68.1 (15.9)
Impact score 52.8 (23.6) 44.2 (29.3) 48.5 (25.2) 45.7 (19.8) 35.9 (24.2) 35.5 (24.9)
Symptoms score 66.7 (16.9) 45.9 (19.4)* 51.1 (19.3)* 64.3 (20.7) 39.5 (23.0)* 49.0 (26.8)*
Total score 62.0 (22.1) 52.9 (26.8)* 58.1 (21.1) 56.7 (17.0) 46.6 (20.4)* 47.7 (20.7)*
Intention-to-treat analysis. Groups: ONS (n=16), Snacks (n=13).
Data shown as mean (SD).
ONS, oral nutritional supplements; SGRQ, St George’s Respiratory Questionnaire.
*Significantly different from baseline, p<0.05.
Figure 3 (A) Energy and (B) protein intake/day during hospitalisation and in follow-up. Total energy and protein intake per kg 
actual body weight at baseline, during hospitalisation versus follow-up. ONS: 28 kcal v 39 kcal, p=0.002 and 1.2 g vs 1.4 g, 
p=0.213. Snacks: 32 kcal vs 40 kcal, p=0.009 and 1.4 g vs 1.8 g, p=0.048. ONS, oral nutritional supplements.
(p<0.01) compared with an increase of 0.8 (SE 0.42) kg/
m2 (p=0.079) and 1.5 (SE 0.65) kg/m2 (p=0.040) in our 
ONS and Snacks groups, respectively. Similar to our study, 
weight increased rapidly in the first months, however in 
their study it remained stable after intervention. Our 
participants might have continued to gain weight if the 
intervention had been provided for a longer duration. 
Although weight remained stable despite no further 
weight gain being achieved, it is important to highlight 
that in the majority of our patients, weight loss, which is 
associated with a higher mortality, was prevented.15 34
It is a limitation that we only assessed compliance 
with two 24-hour recalls early in the follow-up period. 
Future studies should formally assess compliance in 
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the longer term. It can be speculated that long-term 
supplementation is associated with reduced compli-
ance; however, in a systematic review by Hubbard and 
colleagues, no relationship was seen between duration of 
ONS prescription and compliance.35 Although some of 
our patients had previously been advised to take ONS, 
that is, recently or a few years previously, no patients had 
previously been provided with snacks. The quantity of 
the products provided throughout the study period, and 
gradual weight gain in the subjects up to 12 months after 
discharge suggests adequate or good compliance in the 
longer term in both groups.
Another limitation is that although positive results 
were observed in the main outcomes on our study, our 
sample size lacked power to be able to detect a signifi-
cant difference between the two interventions in these 
outcomes. Also, the lack of control group receiving no 
intervention might be considered as a limitation, but 
given the results from previous studies we did not find it 
ethical not providing intervention in this high-risk group.
There are also some practical issues related to the 
approach tested in this trial. Although both interven-
tions were provided free of charge in our study, this is 
not the case in clinical practice. ONS are partly subsi-
dised or provided free of charge to malnourished indi-
viduals in many countries, but general food (snack) is 
not. Furthermore, the concept of our interventions has 
not been economically evaluated. Although each snack 
was cheaper than ONS, the expiry date was shorter and 
therefore the more regular delivery of the snacks might 
lead to greater expense.
Results from this feasibility study suggest that the provi-
sion of both ONS and snacks to patients with COPD is 
feasible on hospital discharge; however, future trials 
should be informed of the recruitment and retention 
issues that have been raised, and the use of functional 
tests as outcome measures in this population merits 
further consideration. Furthermore, future studies 
should include a formal health economic analysis since 
the cost-effectiveness of the two interventions may not be 
the same.
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